Project Grant HT94252310761
Award Date
8/1/23
Completion Date
7/31/26
Dollars Obligated
$769K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
Augusta University Research Institute, Inc. (AURI), a subsidiary of the Board of Regents of the University System of Georgia, received a $808,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program. The three-year award will support AURI's research into the role of neurofibromin 2 (NF2) in vascular smooth muscle cells. NF2 mutations have been linked to various cancers, and this project will investigate medical solutions for conditions...
The Department of the Army Medical Command awarded a $1,155,000 Project Grant to Augusta University Research Institute, Inc. under the Military Medical Research and Development program. The grant will fund research from June 2022 to May 2025 to sensitize prostate cancer to ferropotosis-based therapy. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award supports the program's goal by...
The Defense Health Agency awarded Augusta University Research Institute, Inc. a $1,140,960 Project Grant under the Military Medical Research and Development program to investigate androgen deprivation therapy-mediated cardiovascular disease and vascular aging in men with prostate cancer. The grant aims to study racial differences and the role of NAD+ in these conditions. The four-year award runs from February 23, 2023 through February 22, 2027 and will be performed in Augusta, Georgia. As the...
This Project Grant award of $1,412,000 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a biorepository and community development project to characterize aggressive urothelial cancer variants. The University of Washington, as the prime awardee, will conduct this research over a period of approximately 4 years, from September 2024 through August 2028. The project aims to expand understanding of aggressive forms of urothelial (bladder)...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
This federal Project Grant award of $1,518,817.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research conducted by Weill Medical College of Cornell University to characterize the role of 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The research aims to advance the understanding of how specific genetic factors impact treatment outcomes for this challenging form of cancer, with...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,331,869.00 to Emory University to conduct research on "Therapeutic Targeting of Aurora Kinase A in Lethal Prostate Cancer Using a Novel Inhibitor". The three-year project aims to investigate medical solutions for the battlefield through innovative biomedical research. Emory University is the prime awardee, and they have subcontracted a portion of...
This federal Project Grant award of $1,967,999.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of a CD46 targeted antibody fragment radiopharmaceutical therapy for the treatment of prostate cancer. The award, with a performance period from July 1, 2025 to June 30, 2028, is provided to The Regents of the University of California, San Francisco, a prominent academic medical center and research institution. This...
This Project Grant award in the amount of $1,602,137.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports research to target the MNK/GRP78 pathway to disrupt proteostasis rewiring in castration-resistant prostate cancer. The award, with a performance period from April 15, 2025 to April 14, 2028, is being provided to The University of Kentucky Research Foundation, a non-profit research entity. The research aims...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...